A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

It took years of effort, but one new bill that passed the senate on Thursday will head to Governor Kelly Armstrong’s desk.

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

It was later discovered that one of the donors was HIV positive, leading to her infection..HIV, AIDS, Cancer patient, RCC, Kerala High Court ...